Overview

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Status:
Terminated

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 (pomalidomide) given in combination with cisplatin and etoposide in patients with extensive disease small cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Cisplatin
Etoposide
Etoposide phosphate
Pomalidomide
Thalidomide